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In January 2005, tuberculosis (TB), including multi-
drug-resistant TB (MDR TB), was reported among Hmong 
refugees who were living in or had recently immigrated to 
the United States from a camp in Thailand. We investigated 
TB and drug resistance, enhanced TB screenings, and ex-
panded treatment capacity in the camp. In February 2005, 
272 patients with TB (24 MDR TB) remained in the camp. 
Among 17 MDR TB patients interviewed, 13 were found to 
be linked socially. Of 23 MDR TB isolates genotyped, 20 
were similar according to 3 molecular typing methods. Be-
fore enhanced screening was implemented, 46 TB cases 
(6 MDR TB) were diagnosed in the United States among 
9,455 resettled refugees. After enhanced screening had be-
gun, only 4 TB cases (1 MDR TB), were found among 5,705 
resettled refugees. An MDR TB outbreak among US-bound 
refugees led to importation of disease; enhanced pre-immi-
gration TB screening and treatment decreased subsequent 
importation.
G
lobally, 9 million new cases of tuberculosis (TB) were 
reported in 2004 (1), ≈4.3% of which were multidrug-
resistant TB (MDR TB) (2). MDR TB, deﬁ  ned as infection 
with Mycobacterium tuberculosis resistant to at least isoni-
azid and rifampin, complicates TB control efforts because 
it requires prolonged treatment with drugs that are less po-
tent, more costly, and more toxic than traditional isoniazid- 
and rifampin-based regimens (3,4). These factors challenge 
implementation of effective TB control programs, particu-
larly in developing countries.
Currently, 56% of TB cases in the United States occur 
in foreign-born persons (5), and rates are highest among 
recently arrived immigrants (6,7). Refugee populations are 
particularly vulnerable to TB and drug-resistant TB (8–12). 
Annually, 50,000–70,000 refugees immigrate to the United 
States (13); before entry, they must undergo standard pre-
immigration screening for TB. Despite screening, however, 
refugee populations have exhibited high TB incidence rates 
shortly after arrival in the United States (14–16). One con-
tributor to high postarrival TB rates is the low sensitivity of 
the current pre-immigration TB screening algorithm, which 
has been estimated to identify <35% of all TB cases (17).
In December 2003, the US Department of State an-
nounced a refugee resettlement program for ≈16,000 
Hmong refugees from Laos, who had been living in a tem-
porary camp for displaced persons in Lopburi, Thailand, for 
>10 years. The ﬁ  rst refugees arrived in the United States in 
June 2004; by January 2005, ≈10,000 had immigrated to 
the United States. Initial reports, after health assessments 
of newly arrived refugees, identiﬁ  ed 37 TB cases, 4 of 
which were MDR TB (18). Simultaneously, cases of MDR 
TB were conﬁ  rmed in Thailand in refugees awaiting reset-
tlement. Immigration to the United States was temporarily 
halted in January 2005, while the US Centers for Disease 
Control and Prevention (CDC) and international partners 
investigated the factors that led to emergence and dissemi-
nation of TB, including MDR TB, among these refugees. 
Results from the investigation guided implementation of 
enhanced TB screening and treatment for the ≈6,000 refu-
gees remaining in the camp in Thailand.
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Materials and Methods
This investigation was deemed an urgent public health 
response. Under the federal regulation for the protection of 
human research participants, Code of Federal Regulations 
Title 45, part 46, this investigation was determined by CDC 
to not be human subject research.
Case Deﬁ  nition and Case Detection
Cases were deﬁ  ned by positive sputum smears or cul-
tures or by a physician’s decision to initiate TB treatment 
in the context of radiographic abnormalities and clinical 
features consistent with TB. From April 2004 through 
January 2005, pre-immigration TB screening in the camp 
detected TB cases among the refugees. The TB screening 
algorithm used initially consisted of a medical history, a 
physical examination, and, for applicants >15 years of age, 
a chest radiograph. Persons whose clinical or radiographic 
ﬁ  ndings suggested TB disease submitted 3 sputum speci-
mens for acid-fast bacilli smear microscopy. Limited labo-
ratory capacity was available, and mycobacterial culture 
was performed on sputum samples that were smear positive 
for acid-fast bacilli. Refugees with smear-positive results 
were allowed to travel to the United States after they had 
begun anti-TB treatment and had smear-negative results 
for 3 follow-up sputum specimens. In July 2004, after a 
site visit by CDC and because of concerns about poten-
tial high prevalence of TB, including drug-resistant TB, 
the pre-immigration screening algorithm was expanded to 
include mycobacterial culture and drug-susceptibility test-
ing for both smear-negative and smear-positive specimens. 
From February 2005 (after the TB outbreak was detected) 
through April 2007, suspected TB cases were also identi-
ﬁ  ed through contact tracing.
Patient Interviews
Hmong interpreters interviewed TB patients in the 
camp, using a 24-item questionnaire about history of 
previous TB diagnosis and treatment. When asked about 
previous TB treatment, participants were shown anti-TB 
medications and asked if they had ever taken any of the 
displayed pills in the past. Patient responses were stratiﬁ  ed 
by drug-susceptibility testing results. To assess the possi-
bility of recent MDR TB transmission in the camp, MDR 
TB patients were asked additional questions regarding so-
cial links to other known MDR TB patients. A strong link 
was deﬁ  ned as sharing a household or having contact with 
another MDR TB patient at least 1×/week. A weak link was 
deﬁ  ned as having contact with another MDR TB patient 
<1×/week.
M. tuberculosis Genotyping
Available M .tuberculosis isolates were genotyped by 
spoligotyping (19,20), mycobacterial interspersed repeti-
tive units (MIRUs) (21,22), and IS6110 restriction frag-
ment length polymorphism (RFLP) analysis (23). A cluster 
was deﬁ  ned as >2 M. tuberculosis isolates that had identi-
cal spoligotyping and MIRU results and for which RFLP 
results were identical or differed by only 1 band. To assess 
whether the proportion of MDR TB isolates that clustered 
was greater than that among pansusceptible isolates, we 
used the Fisher exact test with a signiﬁ  cance level of 0.05.
Mapping Patient Households
To assess geographic clustering of cases, we used 
global positioning system (GPS) technology to map TB 
patient households in the camp according to drug-suscepti-
bility testing results. GPS data were analyzed with a spatial 
scan statistic that uses a varying-sized cylinder to encapsu-
late cases within the radius of the cylinders and calculates a 
p value and log likelihood ratio to determine the statistical 
signiﬁ  cance of any clusters that may be detected (24).
Tuberculin Skin Testing
Refugees received tuberculin skin tests (TSTs) to eval-
uate latent TB infection. Induration >5 mm was considered 
a positive test result (25). To assess recent transmission in 
the camp, we summarized and compared TST results for 3 
categories of contacts: 1) a housemate or family member 
of a TB patient with at least 1 sputum smear-positive result 
for acid-fast bacilli; 2) a housemate or family member of 
a TB patient with only sputum smear-negative results; or 
3) not a housemate or family member of a TB patient. Us-
ing those who were not a housemate or family member of a 
TB patient as the referent group, we calculated prevalence 
ratios and 95% conﬁ  dence intervals (CIs) for each expo-
sure group.
Results
From April 2004 through January 2005, TB was diag-
nosed for 272 of the 15,455 refugees screened (Table 1). 
All 272 persons with a TB diagnosis were tested for HIV 
infection; only 1 was infected. Sputum-smear acid-fast ba-
cilli results were available for 247 TB patients; 34 (13.8%) 
were positive. Culture results were available for 242 TB 
patients; 57 (23.6%) patients had positive culture results 
for M. tuberculosis.
Drug-susceptibility testing found that 24 (42.1%) iso-
lates were pansusceptible, 24 (42.1%) were MDR TB, and 9 
(15.8%) were resistant to >1 anti-TB medications but were 
not MDR TB. Drug resistance was found in 9 patterns, 4 
of which were MDR TB. Several additional resistance pat-
terns were noted among the MDR TB isolates: streptomy-
cin (n = 4); streptomycin and ethambutol (n = 15); strepto-
mycin and pyrazinamide (n = 2); streptomycin, ethambutol, 
and pyrazinamide (n = 3). Of the 24 MDR TB patients, 15 
(62.5%) had positive sputum smear results.
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Patient Interviews
Of 272 TB patients, 241 (88.6%) were interviewed. 
Treatment for TB before pre-immigration screenings be-
gan in April 2004 was reported by 15 (6.2%); none had 
received directly observed therapy (DOT). Of the 15 previ-
ously treated patients, 3 (20.0%) had a current diagnosis of 
MDR TB, 1 (6.7%) had TB with isoniazid resistance only, 
1 (7.0%) had TB that was pansusceptible, and 10 (66.7%) 
had received clinical diagnoses without culture conﬁ  rma-
tion. All 3 MDR TB patients who had a history of previous 
treatment had received their treatment during the 3 years 
before their current diagnosis.
After pre-immigration TB screenings started, some 
camp residents visited healthcare providers outside the 
camp to seek treatment for conditions that might have pre-
cluded their passing the pre-immigration medical exami-
nation. Chest radiograph screenings were obtained outside 
the camp by 39 (16.2%) patients during the period between 
when medical screening began at the camp and when their 
own pre-immigration screening was scheduled. Of these, 
32 (82.1%) took TB medications during this time; only 9 
(28.1%) reported that they were told by a doctor or nurse 
that they had TB. Among the remaining 23 patients not re-
porting a diagnosis of TB, 1 (4.3%) had MDR TB, 1 (4.3%) 
had streptomycin-resistant TB, 2 (8.7%) had pansuscep-
tible TB, and the remaining 19 (82.6%) were diagnosed 
clinically without culture conﬁ  rmation.
Of the 24 MDR TB patients, 17 (70.8%) responded to 
the questions regarding social links to other MDR TB pa-
tients (Figure 1.) Among these, 9 (52.9%) reported having 
at least 1 strong link with another MDR TB patient, and 4 
MDR TB patients (23.5%) reported having at least 2 strong 
links with another MDR TB patient. One patient who had 
sputum smear-positive TB (Figure 1, patient 11) was cen-
tral to a social network that linked 13 (76.5%) patients. The 
3 MDR TB patients that had been previously treated for TB 
(Figure 1, patients 1, 2, and 3,) were all directly linked to 
patient 11 and included in the 13-patient network.
TB Genotyping
Genotyping results were available for 46 (80.7%) of 
the 57 culture-conﬁ  rmed cases. Of these, 30 (65.2%) be-
longed to 1 of 5 clusters (clusters A–E), which ranged from 
2 to 20 matching isolates. The remaining 16 (34.8%) iso-
lates were unique (Table 2). The largest culture, cluster C, 
had 20 cases, all of which were MDR TB; they represented 
87.0% of the 23 MDR TB isolates with genotyping results. 
The cluster C spoligotype pattern was 000000000003771, 
and the MIRU pattern was 223325173533. Isolates in clus-
ter C had a 21-band RFLP result. Of the MDR TB isolates 
that were not included in cluster C, 2 had spoligotype and 
RFLP results that matched those included in cluster C, but 
according to MIRU results, they differed at 1 locus. The 
third MDR TB isolate not included in cluster C differed ac-
cording to both MIRU and RFLP results. MDR TB isolates 
were more likely than non–MDR TB isolates to cluster 
(Fisher exact p = 0.02).
Among the 17 MDR TB patients who responded to the 
questions regarding social links to other MDR TB patients 
(Figure 1), 15 (88.2%) were included in cluster C. Isolates 
from patients 5 and 12 matched cluster C according to spo-
ligotype and RFLP results but differed at 1 locus according 
to MIRU results.
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Table 1. Demographic and disease characteristics among 
Hmong refugees with tuberculosis, Thailand, February 2005* 
Characteristic No. (%) 
Total 272 (100) 
Sex 
 F  112  (41.2) 
 M  160  (58.8) 
Age, y  
 <15  21  (7.7) 
 15–64  153  (56.3) 
>65 98 (36.0) 
Culture results 
 Positive  57  (21.0) 
 Negative  185  (68.0) 
 Unknown  30  (11.0) 
DST results 
  MDR TB  24 (8.8) 
 Other  patterns  9  (3.3) 
 Pansusceptible  24  (8.8) 
Smear results 
  Ever positive  34 (12.5) 
 Always  negative  213  (78.3) 
 Unknown  25  (9.2) 
*DST, Mycobacterium tuberculosis drug-susceptibility test results; MDR 
TB, multidrug-resistant tuberculosis. 
Figure 1. Social links between Hmong refugees with multidrug-
resistant tuberculosis, Thailand, February 2005. Numerals indicate 
patients, in order of diagnosis. +, smear positive; –, smear negative; 
dotted lines, weak link; solid lines, strong link.
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As of 2007, genotyping results were available for 7 
additional patients from this camp who had received a di-
agnosis of MDR TB after arrival in the United States (Cali-
fornia). According to spoligotyping and MIRU results, iso-
lates collected from 6 of these patients matched the cluster 
C strain. The seventh isolate had the same spoligotype re-
sult but differed at 1 locus according to MIRU.
Patient Household Maps
TB patients were widely distributed throughout the 
camp living quarters (≈0.5 km2) (Figure 2). The spatial 
analysis showed 3 nonsigniﬁ  cant spatial clusters (p>0.05), 
which suggests no signiﬁ  cant geographic clustering of TB 
patient households, either among all patients or among sub-
sets with similar drug-susceptibility testing patterns.
TST Results
Of the 5,637 camp residents that had TSTs performed 
and results read, 1,624 (28.8%) had positive results. 
Among those who were family members or housemates of 
a camp patient with a sputum smear-positive TB diagno-
sis, 96 (44.0%) had positive TST results. These contacts 
were 1.6× (95% CI 1.4–1.9) as likely as the referent group 
to have a positive result. There was an increased risk (not 
statistically signiﬁ  cant) for a positive result associated with 
being a family member or housemate of a patient with 
sputum smear–negative disease (relative risk = 1.1, 95% 
CI 1.0–1.2). After controlling for patients’ sputum smear 
status, we found that household contacts of patients with 
MDR TB, pansusceptible TB, and TB with some drug re-
sistance had the same risk for a positive TST result.
Modiﬁ  cations and Enhancements to 
Pre-immigration TB Screening and Treatment
After the investigation in February 2005, recommen-
dations for pre-immigration TB screening and treatment 
for Hmong refugees in Thailand were again modiﬁ  ed and 
enhanced (Table 3). These modiﬁ  cations required that all 
refugees >6 months of age be screened with chest radi-
ography. Persons with suspected TB had 3 sputum speci-
mens collected for smear microscopy, culture, and drug-
susceptibility testing with rapid, liquid-based methods. All 
patients were required to show documentation of having 
received DOT for the duration of their TB treatment before 
they were permitted to travel to the United States. In ad-
dition, a TB culture laboratory was built within the camp, 
mechanisms were developed to import quality-assured 
second-line TB medications, and nurses and physicians in 
the camp received advanced training in TB diagnosis and 
treatment. Finally, although TSTs were performed for all 
camp residents during this investigation, the enhanced TB 
screening algorithm required that only those 6 months to 10 
years of age receive TST.
After implementation of the ﬁ  nal enhanced TB screen-
ing and treatment requirements, 97 additional TB cases, in-
cluding 2 MDR TB, were diagnosed in Thailand, resulting 
in an overall total of 369 TB cases. As of April 2007, health 
departments in the United States reported 46 cases of TB, 
6 of which were MDR TB, among 9,455 Hmong refugees 
who immigrated to the United States before implementa-
tion of enhanced screening (487 cases/100,000 persons). In 
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Table 2. Mycobacterium tuberculosis drug-susceptibility test 
results, by genotype, Hmong refugee tuberculosis patients, 
Thailand, February 2005* 
Isolate results 
Genotype 
cluster 
Some
resistance MDR TB  Pansusceptible Total
Unique
isolates
53 81 6
A0 0 3 3
B0 0 2 2
C0 2 0 0 2 0
D0 0 2 2
E1 0 2 3
Total 6 23 17 46
*MDR TB, multidrug-resistant tuberculosis. 
Figure 2. Locations of dwellings within camp for Hmong refugees 
with tuberculosis (TB), Thailand, February 2005. Symbols indicate 
dwellings of patients with the following types of TB: red triangles, 
multidrug-resistant; yellow squares, resistant to >1 anti-TB 
medications but not MDR TB; blue circles, pansusceptible; green 
circles, unknown drug-susceptibility testing results.MDR TB Outbreak, Hmong Refugees, Thailand, 2005
contrast, 4 cases of TB, 1 of which was MDR TB, have 
been diagnosed in the United States among the 5,705 
Hmong refugees who immigrated after implementation of 
enhanced screening (70 cases/100,000 persons). The pro-
portion of cases diagnosed in the United States after the 
enhanced screening was signiﬁ  cantly lower than the pro-
portion diagnosed before the enhanced screening (Fisher 
exact test p<0.001).
Discussion
An outbreak of MDR TB occurred among a popula-
tion in which TB rates were already elevated; as a result, 
TB (some MDR TB) was imported into the United States. 
Several lines of evidence support the conclusion that this 
was an outbreak. First, 13 (76.5%) of 17 MDR TB patients 
interviewed reported having had recent and regular expo-
sure to another MDR TB patient. Although GPS did not 
demonstrate geographic clustering, lack of clustering is not 
unexpected because the camp was small and its population 
density was high, making social networks, rather than ab-
solute physical distance between dwellings, the most im-
portant facilitator of TB transmission. Second, 20 (87.0%) 
of 23 MDR TB isolates were strains that matched by 3 dif-
ferent molecular subtyping methods. It is possible that 2 
additional isolates (22 total) were part of the outbreak as 
well because they matched the outbreak strain according 
to spoligotyping and RFLP results and differed by only 1 
locus according to MIRU; therefore, this difference may 
represent a change in genotype in the same clone over time 
(26). Third, elevated rates of tuberculin reactivity in house-
hold contacts of smear-positive patients suggest substantial 
recent transmission, not simply endemic disease. As rates 
of tuberculin reactivity were elevated in household contacts 
of all smear-positive patients, transmission of pansuscep-
tible TB, TB with drug-resistance but not MDR TB, and 
MDR TB likely occurred in the camp before and during the 
initial resettlement of refugees to the United States in 2004. 
Rates of TST positivity were not presumed to be inﬂ  ated by 
vaccination with M. bovis BCG, because there was no in-
dication or documentation of BCG vaccination among this 
group of refugees.
Delayed recognition of TB transmission in the camp 
had several negative consequences: increased number and 
severity of cases among refugees and importation of TB, 
including MDR TB, into the United States. In addition, 
the costs incurred by the US government were substantial 
and resulted from halting immigration (e.g., cancellation 
of ﬂ  ights, emergency overseas investigations, and program 
enhancements), public health investigations in the United 
States and Thailand, and medical costs of diagnosis and 
treatment. Because half of the cases of MDR TB were spu-
tum smear–negative for acid-fast bacilli, had sputum smear 
microscopy continued to be used as the only tool for ini-
tial screening, the outbreak of MDR TB would likely have 
gone undetected and many more MDR TB cases would 
have been imported into the United States.
Hmong refugees who had a positive TST result did not 
receive treatment for latent TB infection before immigrat-
ing to the United States because they were not contagious 
and thus were eligible to travel on commercial airplanes. 
No universally accepted standard therapy is available for 
latent TB infection with a suspected MDR TB strain. Rath-
er, therapy for suspected latent infection from MDR TB 
is determined on a case-by-case basis in accordance with 
drug-susceptibility testing results from the putative source. 
After arrival in the United States, the receiving local health 
department jurisdictions decided how to evaluate, reevalu-
ate, and treat patients with latent TB infection. Those who 
had no known contact with an MDR TB patient were treat-
ed with isoniazid; those who had had contact with an MDR 
TB patient, either overseas or in California, were treated 
with an MDR TB contact treatment regimen tailored to 
the source case isolate’s susceptibility pattern. Most often, 
they were treated with ﬂ  uoroquinolone and pyrazinamide 
because TB isolates from Hmong refugees were resistant 
to isoniazid, rifampin, and ethambutol. If a patient refused 
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Table 3. Summary of tuberculosis screening algorithm components for Hmong refugees, by date, Thailand* 
CXR
Date
Medical
history 
Physical 
examination TST 1 view  2 views  Sputum smear  Culture
Drug-
susceptibility 
testing
Apr–Jun
2004
Yes Yes  No  Yes,  for  those 
>15 years of 
age
No Yes, if CXR 
indicated
possible TB 
Yes, if 
sputum-smear
positive for 
AFB
No
Jul 2004–
Jan 2005 
Yes Yes  No  Yes,  for  those 
>15 years of 
age
No Yes, if CXR 
indicated
possible TB 
Yes, 
regardless of 
sputum-smear
status
Yes 
Feb
2005–Apr
2007
Yes Yes  Yes,  for 
those 6 mo 
to 10 y of 
age
Yes, for those 
>10 years of 
age
Yes, for those 6 
mo to 10 y of 
age
Yes, if CXR 
indicated
possible TB 
Yes, 
regardless of 
sputum-smear
status
Yes 
*TST, tuberculin skin test; CXR, chest radiograph; TB, tuberculosis; AFB, acid-fast bacilli. RESEARCH
medication for latent TB infection, that patient was closely 
clinically monitored for 2 years.
This outbreak led to major changes in public health 
practice for this refugee group and in future pre-immigra-
tion medical screening policies. Enhancements to pre-im-
migration TB screening (Table 3) contributed to a reduc-
tion in the number of imported TB cases. As a result, CDC 
is working with the US Department of State, panel phy-
sicians, the International Organization for Migration, and 
other organizations to implement similar enhancements to 
general pre-immigration TB screening guidelines. These 
new technical instructions are being implemented ﬁ  rst in 
priority countries, as determined by immigration patterns 
and TB prevalence. Eventually, all refugees and immigrants 
entering the United States will be screened with a revised 
TB screening algorithm that includes mycobacterial culture 
and susceptibility testing. Since the end of 2007, applicants 
for US immigration who have been screened according to 
the new technical instructions have originated from Mexi-
co, the Philippines, Nepal, and Thailand. CDC notiﬁ  es US 
state and local health departments when panel physicians 
in a speciﬁ  c country begin implementing this revised al-
gorithm. Ongoing US national TB surveillance will help 
determine the effect of this effort on reducing the number 
of foreign-born persons with TB living in the United States. 
In this outbreak investigation, 3 MDR TB patients were 
identiﬁ  ed who had received treatment in the past 3 years 
at healthcare facilities outside the refugee camp; however, 
none reported having received DOT, the strategy recom-
mended for reducing emergence of drug resistance (27). 
Our ﬁ  ndings support the goals of the World Health Orga-
nization’s second Global Plan to Stop TB, which includes 
refugees as a high-risk group requiring attention by TB 
control programs. This outbreak also highlights the need 
for US public health preparedness efforts to focus on con-
tainment of threats of emergent diseases, such as MDR TB, 
at their source (28).
To control TB and prevent MDR TB, multiple orga-
nizations—including government agencies, multilateral 
agencies, and nongovernment organizations—must work 
together to provide high-quality TB diagnosis and treatment 
consistent with international standards of care in both host 
and receiving countries (29). For low-incidence countries, 
such as the United States, investing in global TB control is 
a cost-effective strategy for reducing TB, domestically and 
globally (30,31).
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